Media stories about Sanofi (NYSE:SNY) have been trending very positive recently, according to Accern. The research firm identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sanofi earned a news impact score of 0.51 on Accern’s scale. Accern also assigned news headlines about the company an impact score of 0 out of 100, indicating that recent media coverage is extremely unlikely to have an impact on the stock’s share price in the next few days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s scoring:
- Sanofi upgraded by BidaskClub to hold. https://t.co/YDXn7KW6Gu $SNY #SNY (4-traders.com)
- Sanofi (SNY) Upgraded by BidaskClub to Hold (americanbankingnews.com)
- Regeneron to terminate antibody discovery partnership with Sanofi at year-end – Seeking Alpha (seekingalpha.com)
- The Surprising Reason Regeneron Toppled Despite Its Beat-And-Raise – Investor’s Business Daily (investors.com)
- Sanofi Q2/2017: Mixed Signals – Seeking Alpha (seekingalpha.com)
Shares of Sanofi (NYSE SNY) traded up 0.84% during trading on Friday, reaching $48.08. 1,172,670 shares of the company were exchanged. The firm’s 50 day moving average price is $48.11 and its 200 day moving average price is $45.82. The company has a market capitalization of $120.75 billion, a PE ratio of 11.54 and a beta of 0.88. Sanofi has a one year low of $36.81 and a one year high of $50.24.
Sanofi (NYSE:SNY) last announced its quarterly earnings results on Monday, July 31st. The company reported $0.74 EPS for the quarter, meeting analysts’ consensus estimates of $0.74. Sanofi had a return on equity of 25.34% and a net margin of 25.89%. The company had revenue of $8.66 billion during the quarter, compared to analyst estimates of $8.71 billion. Sanofi’s revenue was down 2.3% on a year-over-year basis. Equities research analysts forecast that Sanofi will post $3.23 earnings per share for the current fiscal year.
A number of research firms have recently issued reports on SNY. Berenberg Bank downgraded shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, May 11th. BidaskClub upgraded shares of Sanofi from a “hold” rating to a “buy” rating in a report on Friday, June 23rd. Zacks Investment Research upgraded shares of Sanofi from a “hold” rating to a “buy” rating and set a $55.00 price objective on the stock in a report on Friday, June 2nd. Argus lifted their price objective on shares of Sanofi from $50.00 to $55.00 and gave the company a “buy” rating in a report on Friday, June 9th. Finally, Cowen and Company reiterated a “market perform” rating and issued a $52.00 price objective (up from $46.00) on shares of Sanofi in a report on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. The company currently has a consensus rating of “Hold” and an average target price of $63.75.
COPYRIGHT VIOLATION NOTICE: “Sanofi (NYSE:SNY) Receives News Impact Rating of 0.51” was originally published by BBNS and is owned by of BBNS. If you are reading this article on another site, it was copied illegally and republished in violation of US and international copyright & trademark laws. The correct version of this article can be read at https://baseballnewssource.com/markets/sanofi-nysesny-getting-very-favorable-press-coverage-report-shows-updated-updated-updated/1180211.html.
Sanofi Company Profile
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. The Company’s segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with our FREE daily email newsletter.